{"id":809890,"date":"2025-02-06T08:38:55","date_gmt":"2025-02-06T13:38:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/"},"modified":"2025-02-06T08:38:55","modified_gmt":"2025-02-06T13:38:55","slug":"myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/","title":{"rendered":"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test"},"content":{"rendered":"
\n

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc<\/a>. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life<\/a> members.<\/p>\n

The agreement enables more than one million individuals within CancerCARE\u2019s network to assess their eligibility for the MyRisk test by taking the MyGeneHistory<\/a>\u00ae<\/sup><\/a> quiz, a guideline-based online patient screening tool. If they meet criteria, they can be directed to a clinician who can order the MyRisk<\/a>\u00ae<\/sup><\/a> with RiskScore<\/a>\u00ae<\/sup><\/a> Hereditary Cancer Test<\/a> on their behalf. Patients who take the MyRisk test can then review their results with a Myriad genetic counselor.<\/p>\n

\u201cMyRisk\u2019s clear, actionable results provide the foundation for personalized care plans, empowering patients to make confident, informed decisions about their medical management,\u201d said Melissa Gonzales, President, Women\u2019s Health, Myriad Genetics. \u201cExpanding access through CancerCARE\u2019s network will give more patients the opportunity to take the MyRisk with RiskScore Hereditary Cancer Test.\u201d<\/p>\n

MyRisk with RiskScore is the first and industry-leading hereditary cancer test and polygenic risk prediction test for all ancestries. MyRisk evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with an individualized five-year and remaining lifetime breast cancer risk assessment.<\/p>\n

\u201cWorking with Myriad Genetics is extremely important, and we look forward to enhancing our relationship over time. We share a common goal of educating and enabling consumers to access early genetic screening to support personal and family health,\u201d said Oscar Bronsther, MD, Chief Medical Officer at CancerCARE for Life. \u201cWe are excited to provide our members with access to the MyRisk Hereditary Cancer Test, which can help identify patients who may be at increased risk of developing cancer.\u201d<\/p>\n

Myriad\u2019s Breast Cancer Risk Assessment Program features the MyRisk with RiskScore Hereditary Cancer Test, the first and industry-leading hereditary cancer test and polygenic breast cancer risk assessment for all ancestries. It includes MyGeneHistory, an online screening tool that helps assess if a patient meets medical guidelines for hereditary cancer testing. The program also includes patient education about genetic testing and a guide on how to collect family history of certain cancers. For more information, please visit Myriad.com\/seemore<\/a>.<\/p>\n

\n About CancerCARE<\/strong>
\n
CancerCARE and CancerCARE for Life comprise one of the nation\u2019s largest prevention, early detection and cancer management programs. CancerCARE for Life\u2019s unique approach blends targeted education and awareness with personalized oncology trained nurses and physicians to deliver an exceptional member experience. Expertise in clinical trials, Center of Excellence (COE) access, pre-guideline care, NCCN1<\/sup> Guideline\u00ae<\/sup> care, and gene and cellular therapy help ensure the best outcomes for members.<\/p>\n

\n About Myriad Genetics<\/strong>
\n
Myriad Genetics is a leading genetic and genomic tumor testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com<\/a>.<\/p>\n

\n Safe Harbor Statement\u00a0 \u00a0<\/strong>
\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company\u2019s collaboration with CancerCARE for Life and its potential to expand patient access to the MyRisk with RiskScore Hereditary Cancer Test, empowering patients to make confident, informed decisions about their medical management. These \u201cforward-looking statements\u201d are management\u2019s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company\u2019s filings with the U.S. Securities and Exchange Commission, including the company\u2019s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company\u2019s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.\u00a0<\/p>\n

\n Investor Contact\u00a0<\/strong>
\n
Matt Scalo\u00a0
(801) 584-3532\u00a0
IR@myriad.com<\/u><\/a>\u00a0<\/p>\n

\n Media Contact\u00a0<\/strong>
\n
Kate Schraml
(224) 875-4493
PR@myriad.com<\/u><\/a>\u00a0\u00a0<\/p>\n

\n 1<\/sup> National Comprehensive Cancer Network (NCCN) makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members. The agreement enables more than one million individuals within CancerCARE\u2019s network to assess their eligibility for the MyRisk test by taking the MyGeneHistory\u00ae quiz, a guideline-based online patient screening tool. If they meet criteria, they can be directed to a clinician who can order the MyRisk\u00ae with RiskScore\u00ae Hereditary Cancer Test on their behalf. Patients who take the MyRisk test can then review their results with a Myriad genetic counselor. \u201cMyRisk\u2019s clear, … <\/p>\n

Continue reading “Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-809890","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMyriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members. The agreement enables more than one million individuals within CancerCARE\u2019s network to assess their eligibility for the MyRisk test by taking the MyGeneHistory\u00ae quiz, a guideline-based online patient screening tool. If they meet criteria, they can be directed to a clinician who can order the MyRisk\u00ae with RiskScore\u00ae Hereditary Cancer Test on their behalf. Patients who take the MyRisk test can then review their results with a Myriad genetic counselor. \u201cMyRisk\u2019s clear, … Continue reading "Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-06T13:38:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzg5NiM2NzM4MjkwIzIwMDc4ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test\",\"datePublished\":\"2025-02-06T13:38:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/\"},\"wordCount\":795,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzg5NiM2NzM4MjkwIzIwMDc4ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/\",\"name\":\"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzg5NiM2NzM4MjkwIzIwMDc4ODc=\",\"datePublished\":\"2025-02-06T13:38:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzg5NiM2NzM4MjkwIzIwMDc4ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzg5NiM2NzM4MjkwIzIwMDc4ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/","og_locale":"en_US","og_type":"article","og_title":"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test - Market Newsdesk","og_description":"SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members. The agreement enables more than one million individuals within CancerCARE\u2019s network to assess their eligibility for the MyRisk test by taking the MyGeneHistory\u00ae quiz, a guideline-based online patient screening tool. If they meet criteria, they can be directed to a clinician who can order the MyRisk\u00ae with RiskScore\u00ae Hereditary Cancer Test on their behalf. Patients who take the MyRisk test can then review their results with a Myriad genetic counselor. \u201cMyRisk\u2019s clear, … Continue reading \"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-06T13:38:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzg5NiM2NzM4MjkwIzIwMDc4ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test","datePublished":"2025-02-06T13:38:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/"},"wordCount":795,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzg5NiM2NzM4MjkwIzIwMDc4ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/","name":"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzg5NiM2NzM4MjkwIzIwMDc4ODc=","datePublished":"2025-02-06T13:38:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzg5NiM2NzM4MjkwIzIwMDc4ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzg5NiM2NzM4MjkwIzIwMDc4ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-with-riskscore-hereditary-cancer-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=809890"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809890\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=809890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=809890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=809890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}